Hydroxychloroquine does not seem to be effective against Covid-19, either in severely or more mildly affected patients, according to two studies published Thursday, May 14 in the British journal BMJ.
British medical journal BMJ, which publishes the two studies, in a press release said “Taken together, these results do not support the use of hydroxychloroquine as a routine treatment for patients with Covid-19”
The first study involved 181 adult patients admitted to hospital with Covid-19 which required oxygen. Led by French researchers, it concludes that hydroxychloroquine, a derivative of the antimalarial chloroquine, does not significantly reduce the risks of admission to intensive care or death in patients hospitalized with pneumonia due to Covid-19.
In total, 84 of these patients received hydroxychloroquine daily less than two days after their hospitalization, unlike the other 97. Whether or not receiving this treatment did not change anything, whether for transfers to the ICU (76% of the patients treated with hydroxychloroquine were in ICU after the 21st day, compared to 75% in the other group. patients) or for mortality (the 21st day survival rate was 89% and 91% respectively).
More side effects
The second study involved 150 adults hospitalized in China with mainly “mild” or “moderate” forms of Covid-19. Half received hydroxychloroquine, the other half did not.
The Chinese team at the origin of the study, notes that this treatment recommended by Professor Didier Raoult, does not make it possible to eliminate the virus more quickly than standard treatments in patients hospitalized with a “mild” or ” moderate “from Covid-19.
In addition, the side effects are more significant (30% of those who had received hydroxychloroquine suffered from adverse effects). The most common was diarrhea compared to 9% in patients who had not taken it.